Product name: Timosaponin AIII
Synonym name: Timosaponin A3; Filiferin B; Anemarsaponin A3; Xilingsaponin A

Catalogue No.: BP1395
Cas No.: 41059-79-4
Formula: C₃₉H₆₄O₁₃
Mol Weight: 740.928
Botanical Source: Anemarrhena asphodeloides Bge.
Physical Description:
Type of Compound: Steroids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.




Chengdu Biopurify Phytochemicals Ltd. is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，TCM), Natural Active Pharmaceutical Ingredients worldwide.
The main services:
A. Supply active ingredients and reference standards of TCM, from mgs to kgs scale
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR(contract research), CM(contract manufacture) and PD(process development) services from lab scale, pilot scale to commercial scale(GMP is also available)
E. TCM compounds library for drug screen,more than 3000 compounds available, many of them are rare and unique.

HPLC of Timosaponin AIII

HNMR of Timosaponin AIII

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Timosaponin AIII (CAS No.: 41059-79-4) is the main active ingredient derived from the traditional Chinese medicine Anemarrhena asphodeloides Bunge, and belongs to the steroid saponin class. In recent years, with the deepening of pharmacological research on natural products, anemaritol saponin AIII has attracted attention due to its multi-target and multifunctional biological activity. It has demonstrated remarkable pharmacological potential especially in anti-inflammatory properties, neuroprotection, and antitumor treatments. Its inhibitory effect on acetylcholinesterase (AChE) (IC50 = 35.4 μM) suggests its potential for application in neurodegenerative diseases such as Alzheimer's disease (AD). In addition, anemarhasaponin AIII regulates various inflammation-related signaling pathways and molecular targets, demonstrating good anti-inflammatory activity, providing a theoretical basis for its development as a novel anti-inflammatory drug. This paper will systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, druggability, and clinical application prospects of Anemaranthin Saponin AIII, aiming to provide references for subsequent basic research and drug development.

Chemical structure and physicochemical properties

Anemarrhena saponin AIII is a typical steroidal saponin with the molecular formula C₄₁H₆₆O₁₂, molecular weight 740.9280, and its structure includes a steroid backbone and multiple glycosyl residues. Its steroid core structure imparts strong bioactivity, while the glycosyl component affects its water solubility and bioavailability. In terms of physicochemical properties, the LogP value of anemarrhenia saponin AIII is 2.2219, indicating moderate lipid solubility that facilitates cell membrane penetration; TPSA (polar surface area) is 196.9900, indicating good solubility in polar environments but may also limit its ability to cross the blood-brain barrier. Low water solubility (0.0231 mg/mL) suggests limited solubility in the body, suggesting that bioavailability may be improved through formulation techniques. In terms of pharmacological safety, anemaritol saponin AIII does not inhibit hERG channels, and Ames-induced mutagenic tests are negative, indicating good safety potential.

Plant Origins and Extraction Methods

Anemarrhena saponin AIII is mainly found in the rhizomes of Anemarrhena asphodeloides Bunge, a plant in the lily family. As a traditional Chinese medicinal herb, anemarrhena has a long history and is widely used in traditional treatments such as clearing heat and purging fire, moistening dryness, and quenching thirst. Modern research shows that anemarrhenia saponin AIII is one of its main active ingredients.

The extraction method typically uses organic solvent extraction combined with column chromatography separation technology. The specific steps include:

1. Raw material pretreatment: Crush the dried anemarrhena rhizome to an appropriate particle size.
2. Solvent extraction: Multiple reflux extractions are performed using polar organic solvents such as methanol or ethanol to improve extraction efficiency.
3. Crude extract concentration: solvent is removed by vacuum concentration to obtain concentrated extracts.
4. Separation and purification: Using silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and other techniques, combined with gradient elution, anemaritol saponin AIII was isolated and purified.
5. Structural identification: Confirm its structure using methods such as mass spectrometry (MS) and nuclear magnetic resonance (NMR).

In recent years, new technologies such as ultrasound-assisted extraction and microwave-assisted extraction have also been applied to the extraction of anemaritol saponin AIII, improving extraction efficiency and purity.

Pharmacological activity research

Anti-inflammatory activity

Anemarrhena saponin AIII has been studied in relatively in-depth anti-inflammatory fields. It can significantly inhibit the production and release of inflammatory mediators, such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6). Both in vitro cell and animal inflammation models showed that anemarhasaponin AIII reduces inflammatory responses and alleviates tissue damage by downregulating the expression of multiple inflammation-related genes.

Anti-acetylcholinesterase activity

Anemara saponin AIII inhibits acetylcholinesterase (AChE), with an IC50 value of 35.4 μM. AChE is a key enzyme in the nervous system that degrades acetylcholine. Inhibiting AChE activity can increase acetylcholine levels and improve cognitive function, suggesting the potential application value of anemogen saponin AIII in neurodegenerative diseases.

Other pharmacological activities

In addition to anti-inflammatory and AChE inhibition, anemaritol saponin AIII also exhibits various biological activities including anti-tumor, antioxidant, and neuroprotective effects. For example, in various tumor cell lines, anemarmoside saponin AIII can induce apoptosis and inhibit cell proliferation. Its antioxidant effect works by scavenging free radicals, reducing oxidative stress damage, and protecting cellular function.

Mechanism of action and molecular targets

The pharmacological effects of anemarthenin saponin AIII involve multiple signaling pathways and molecular targets, mainly including:

• IL-6/STAT3 pathway: Anemarite saponin AIII can inhibit IL-6 expression and the activation of its downstream signal transduction factor STAT3, blocking pro-inflammatory signals and reducing inflammatory responses.
• NFKB1 pathway: By inhibiting the nuclear factor κB (NF-κB) signaling pathway, it lowers the transcription level of inflammatory mediators and decreases the release of inflammatory factors.
• CASP1 (caspase-1): Affects the activation of inflammasomes and regulates the initiation of inflammatory responses.
• TRPV1 and TRPA1 channels: regulate pain and inflammatory responses, and relieve inflammation-related pain symptoms.
• PTGS1 and PTGS2 (COX-1 and COX-2): Inhibit cyclooxygenase activity, reduce prostaglandin synthesis, and exert anti-inflammatory and analgesic effects.
• TNF and NOS2: regulate pro-inflammatory cytokines and induced nitric oxide synthase expression, reducing inflammatory damage.

Additionally, anemarmoside AIII enhances acetylcholine signaling by inhibiting AChE activity, helping to improve neuroprotection and cognitive function.

Druggability evaluation and pharmacokinetics

Druggability parameters

Anemartherosin AIII has a relatively large molecular weight (740.9280), which may to some extent limit its oral absorption and cell membrane penetration. Its LogP value of 2.2219 indicates moderate lipid solubility, which is beneficial for transmembrane transport, but high TPSA (196.99) and low water solubility (0.0231 mg/mL) suggest higher polarity, which may affect bioavailability and tissue distribution. The blood-brain barrier has a relatively low permeability that limits its direct role in central nervous system diseases, but it still holds potential value by modulating the peripheral nervous system and the inflammatory environment.

In terms of safety, anemaritol saponin AIII does not inhibit hERG channels, reducing arrhythmia risk, and the Ames test was negative, indicating a low risk of mutagenic behavior and a solid safety foundation.

Pharmacokinetics

Currently, systematic pharmacokinetic research on anemarrhenin saponin AIII is relatively limited. Previous studies have shown that after oral administration, plasma concentrations are low, suggesting a first-pass effect and poor oral absorption. Metabolic pathways mainly involve hepatic enzyme systems, possibly through glycoside hydrolysis and metabolic transformation of the steroid skeleton. Future pharmacokinetic studies are needed to optimize administration methods and dosage form designs to improve bioavailability and therapeutic efficacy.

Prospects and outlooks for clinical applications

Zymatrosaponin AIII, due to its multi-target and multifunctional pharmacological properties, demonstrates broad clinical application potential in anti-inflammation, neuroprotection, and antitumor fields. Its inhibitory effect on AChE opens the possibility for developing novel therapeutic drugs for neurodegenerative diseases such as Alzheimer's disease. The diversity of anti-inflammatory mechanisms gives it promising application prospects in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

However, the high molecular weight, low water solubility, and limited blood-brain barrier penetration ability of anemarhasamine saponin AIII are the main obstacles to its clinical translation. Future research should focus on:

• Drug formulation optimization: Improving solubility and bioavailability through novel delivery systems such as nanocarriers and liposomes.
• Structural modification: Chemical modification reduces molecular polarity, enhancing membrane permeability and metabolic stability.
• Systematic pharmacokinetic studies: clarify its absorption, distribution, metabolism, and excretion characteristics in vivo, guiding clinical medication protocols.
• Preclinical and clinical trials: Verify safety, efficacy, and dosage ranges to promote clinical application.

Combined with modern drug development technologies, anemarinal saponin AIII is expected to become an important candidate molecule in the development of natural product drugs.

Conclusion

As a key active ingredient in anemarrhena, AIII demonstrates significant pharmacological value due to its multi-target anti-inflammatory and neuroprotective effects. Its inhibitory effect on acetylcholinesterase offers new ideas for the treatment of neurodegenerative diseases. Despite challenges in druggability, with the support of modern drug design and formulation technology, the clinical translation prospects of Anemaranthinosaponin AIII are broad. In-depth mechanistic research, pharmacokinetic analysis, and clinical validation in the future will lay a solid foundation for it to become a novel natural medicine, promoting the application and development of natural products in modern medicine.